# OnCo record paper-naliricc-lancet-gastroenterol-hepatol-2024 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-naliricc-lancet-gastroenterol-hepatol-2024/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-naliricc-lancet-gastroenterol-hepatol-2024" ;
  schema:name "Nanoliposomal irinotecan and fluorouracil plus leucovorin versus fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based therapies (AIO NALIRICC): a multicentre, open-label, randomised, phase 2 trial"@en ;
  schema:description "Published report from the NALIRICC trial registered as NCT03043547, in The lancet. Gastroenterology & hepatology (2024), chosen as the most cited paper whose own text cites the registry id."@en ;
  schema:url <https://onco.cc/key-papers/paper-naliricc-lancet-gastroenterol-hepatol-2024/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/s2468-1253(24)00119-5>, <https://pubmed.ncbi.nlm.nih.gov/38870977/>, <https://europepmc.org/article/MED/38870977>, <https://clinicaltrials.gov/study/NCT03043547> ;
  onco:tag "europepmc-ingest" ;
  schema:sameAs <https://doi.org/10.1016/s2468-1253(24)00119-5> ;
  schema:datePublished "2024"^^xsd:gYear ;
  schema:author "Vogel A, Saborowski A, Wenzel P, et al." ;
  onco:trials <https://onco.cc/trials/naliricc/> .